Xu SW - Search Results

1

Urolithin A promotes atherosclerotic plaque stability by limiting inflammation and hypercholesteremia in Apolipoprotein E-deficient mice.

Xu MY, Xu JJ, Kang LJ, Liu ZH, Su MM, Zhao WQ, Wang ZH, Sun L, Xiao JB, Evans PC, Tian XY, Wang L, Huang Y, Liang XM, Weng JP, Xu SW. Xu MY, et al. Among authors: xu sw. Acta Pharmacol Sin. 2024 Nov;45(11):2277-2289. doi: 10.1038/s41401-024-01317-5. Epub 2024 Jun 17. Acta Pharmacol Sin. 2024. PMID: 38886550

2

Editorial: Epigenetic Regulation in Cardiovascular Diseases.

Pillai ICL, Xu S, Rau CD, Wang Z. Pillai ICL, et al. Front Cardiovasc Med. 2022 Jan 11;8:831851. doi: 10.3389/fcvm.2021.831851. eCollection 2021. Front Cardiovasc Med. 2022. PMID: 35087888 Free PMC article. No abstract available.

3

Targeting FGF21 in cardiovascular and metabolic diseases: from mechanism to medicine.

Tan H, Yue T, Chen Z, Wu W, Xu S, Weng J. Tan H, et al. Int J Biol Sci. 2023 Jan 1;19(1):66-88. doi: 10.7150/ijbs.73936. eCollection 2023. Int J Biol Sci. 2023. PMID: 36594101 Free PMC article. Review.

4

ASGR1: an emerging therapeutic target in hypercholesterolemia.

Zhao W, Xu S, Weng J. Zhao W, et al. Signal Transduct Target Ther. 2023 Jan 23;8(1):43. doi: 10.1038/s41392-023-01319-5. Signal Transduct Target Ther. 2023. PMID: 36690631 Free PMC article. No abstract available.

5

Editorial: Epigenetic regulation in cardiovascular diseases, volume II.

Xu S, Pillai ICL, Rau CD, Wang Z. Xu S, et al. Front Cardiovasc Med. 2023 Mar 6;10:1166268. doi: 10.3389/fcvm.2023.1166268. eCollection 2023. Front Cardiovasc Med. 2023. PMID: 36950284 Free PMC article. No abstract available.

6

Transcription factor 21 accelerates vascular calcification in mice by activating the IL-6/STAT3 signaling pathway and the interplay between VSMCs and ECs.

Zhao XK, Zhu MM, Wang SN, Zhang TT, Wei XN, Wang CY, Zheng J, Zhu WY, Jiang MX, Xu SW, Yang XX, Duan YJ, Zhang BC, Han JH, Miao QR, Hu H, Chen YL. Zhao XK, et al. Among authors: xu sw. Acta Pharmacol Sin. 2023 Aug;44(8):1625-1636. doi: 10.1038/s41401-023-01077-8. Epub 2023 Mar 30. Acta Pharmacol Sin. 2023. PMID: 36997664 Free PMC article.

7

Aprocitentan, a dual endothelin-1 (ET-1) antagonist for treating resistant hypertension: Mechanism of action and therapeutic potential.

Xu J, Jiang X, Xu S. Xu J, et al. Drug Discov Today. 2023 Nov;28(11):103788. doi: 10.1016/j.drudis.2023.103788. Epub 2023 Sep 22. Drug Discov Today. 2023. PMID: 37742911 Review.

8

A proteome-wide screen identifies the calcium binding proteins, S100A8/S100A9, as clinically relevant therapeutic targets in aortic dissection.

Jiang H, Zhao Y, Su M, Sun L, Chen M, Zhang Z, Ilyas I, Wang Z, Little PJ, Wang L, Weng J, Ge J, Xu S. Jiang H, et al. Pharmacol Res. 2024 Jan;199:107029. doi: 10.1016/j.phrs.2023.107029. Epub 2023 Dec 5. Pharmacol Res. 2024. PMID: 38056513 Free article.

9

TRIM56 protects against nonalcoholic fatty liver disease by promoting the degradation of fatty acid synthase.

Xu S, Wu X, Wang S, Xu M, Fang T, Ma X, Chen M, Fu J, Guo J, Tian S, Tian T, Cheng X, Yang H, Zhou J, Wang Z, Yin Y, Xu W, Xu F, Yan J, Wang Z, Luo S, Zhang XJ, Ji YX, Weng J. Xu S, et al. J Clin Invest. 2024 Jan 11;134(5):e166149. doi: 10.1172/JCI166149. J Clin Invest. 2024. PMID: 38206764 Free PMC article.

10

NAFLD and NASH: etiology, targets and emerging therapies.

Wei S, Wang L, Evans PC, Xu S. Wei S, et al. Drug Discov Today. 2024 Mar;29(3):103910. doi: 10.1016/j.drudis.2024.103910. Epub 2024 Feb 1. Drug Discov Today. 2024. PMID: 38301798 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

234 results

Search Page

Filters